UNSPSC 51384604: Bendazac or bendazolic acid

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G4AG71204O, chemically known as acetic acid, ((1-(phenylmethyl)-1h-indazol-3-yl)oxy)- but generally known as bendazac, which bears US NIH Compound Identifier 2313. Bendazac most often comes in base, lysine, methyl ester, and sodium forms. European Medicines Agency schedules Bendazac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05708MIG.

UNSPSC 51384604 Bendazac or bendazolic acid is a Commodity code that in recent state and local procurement activity covers the purchase of pharmaceutical products—notably naloxone, generic multi-source pharmaceuticals, and over-the-counter products—supplied through authorized wholesaler networks and direct-to-manufacturer channels. State and local buyers under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, for example, issued an IFB seeking 1,900 units of naloxone annually through competitive bidding, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. The Texas Health and Human Services Commission posted an RFI exploring vendor capabilities for implementing a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity concentrates in Texas, Minnesota, and Florida. The MMCAP RFP (response due March 26, 2026) requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with pricing weighted 75 percent on competitiveness and products effective July 1, 2026; vendors must maintain $5 million commercial general liability insurance and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Seminole County's IFB (due July 26, 2023) requires quarterly deliveries of naloxone and safe drug deactivation systems with vendor responsibility for all shipping and delivery costs; the contract includes a three-month probationary period and potential FEMA funding with associated federal compliance requirements. The Texas RFI seeks market intelligence on direct contracting models without traditional intermediaries, with no formal evaluation criteria or budget specified at the information-gathering stage.